GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Beginning Cash Position

Mesoblast (Mesoblast) Beginning Cash Position : $40.85 Mil (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Beginning Cash Position?

Mesoblast's Beginning Cash Position for the quarter that ended in Dec. 2023 was $40.85 Mil.

Mesoblast's quarterly Beginning Cash Position increased from Jun. 2023 ($48.80 Mil) to Sep. 2023 ($71.32 Mil) but then declined from Sep. 2023 ($71.32 Mil) to Dec. 2023 ($40.85 Mil).

Mesoblast's annual Beginning Cash Position increased from Jun. 2021 ($129.33 Mil) to Jun. 2022 ($136.88 Mil) but then declined from Jun. 2022 ($136.88 Mil) to Jun. 2023 ($60.45 Mil).


Mesoblast Beginning Cash Position Historical Data

The historical data trend for Mesoblast's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Beginning Cash Position Chart

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.76 50.43 129.33 136.88 60.45

Mesoblast Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.62 48.80 71.32 40.85 77.55

Mesoblast Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.


Mesoblast Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Mesoblast's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast (Mesoblast) Business Description

Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.